Ironwood Pharmaceuticals Investor Relations Material
Latest events
Q3 2023
Ironwood Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Ironwood Pharmaceuticals, Inc., is a healthcare company that focuses on the development and commercialization of gastrointestinal products. The company develops linaclotide, a guanylate cyclase type-C agonist for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation under the LINZESS name in the United States and under the CONSTELLA name in Europe; and lesinurad for gout.
Key slides for Ironwood Pharmaceuticals Inc
Q2 2023
Ironwood Pharmaceuticals Inc
Q3 2023
Ironwood Pharmaceuticals Inc
Latest articles
Marvel-ous Reporting: Marvel’s Comic Inspired Reports
Shareholder reports are often considered tedious and dry. However, in the late 1980s and early 1990s, Marvel Comics revolutionized this perception by transforming its financial reports into captivating comic books.
8 Dec 2023
The Payments Value Chain: A Complex Ecosystem
The payments industry is a complex and dynamic field involving multiple key players. These include customers, merchants, issuers, acquirers, card networks, and various other entities together forming the payments value chain.
8 Dec 2023
NIBE: Creating Millionaires and a Greener Future
NIBE, just like IKEA, was founded in a rural part of Sweden called Småland. The company offers a wide range of pumps, wood stoves, and solar panels.
6 Dec 2023
Ticker symbol
IRWD
Country
🇺🇸 United States